The Patent Finder
AR

Amgen Research (Munich) GmbH

First filing 2006
OverviewNotableFeesChangesFamiliesPatent listSources & methods

26 patents currently held

26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Jul 2027. from the record

Of the 26 now held by other companies, 21 name Amgen Inc. as their current owner, and 5 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jul 2027
Next term end
15
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Composition Comprising Cross-Species-Sepecific Antibodies and Uses Thereof US 8,236,308
The most cited patent in this portfolio, cited by 326 later US patents, top 1% of utility patents granted in 2012 in our data. Protection runs to 2028.
Ends Apr 2028 · High confidence
Also notable
Antibody Constructs for DLL3 and CD3 US 10,294,300
Cited by 68 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Ends Aug 2036 · High confidence
Also notable
Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens US 9,260,522
Cited by 113 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Apr 2031 · High confidence

Formerly held, still cited

Notable
Cited by 18 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Amgen Inc.
Ends Nov 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due May 24, 2027
    The maintenance fee for Means and Methods for Treating Dlbcl (US 9,192,665) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
  • 1 fee due Aug 16, 2027
    The maintenance fee for Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens (US 9,260,522) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Compositions Comprising Cross-Species-Specific Antibodies and Uses Thereof (US 11,925,684) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 4 of the patents on this record were granted since Aug 22, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 11,154,617Means and Methods for the Treament of B Cell Non-Hodgkin Lymphoma and B Cell Leukemia
In force
 · Medium confidence
In forceMedium confidence
US 8,007,796Means and Methods for the Treatment of Tumorous Diseases
In force
 · High confidence
In forceHigh confidence
US 8,236,308Composition Comprising Cross-Species-Sepecific Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 11,925,684Compositions Comprising Cross-Species-Specific Antibodies and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,047,159Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens
In force
 · High confidence
In forceHigh confidence
US 9,260,522Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens
In force
 · High confidence
In forceHigh confidence
US 10,696,744Means and Methods for Treating Dlbcl
In force
 · Medium confidence
In forceMedium confidence
US 11,633,408Prevention of Adverse Effects Caused by CD3 Specific Binding Domains
In force
 · Low confidence
In forceLow confidence
US 9,192,665Means and Methods for Treating Dlbcl
In force
 · High confidence
In forceHigh confidence
US 11,579,142Dosage Regimen for Administering a CD19XCD3 Bispecific Antibody to Patients at Risk for Potential Adverse Effects
In force
 · Low confidence
In forceLow confidence
10 of 26 patents shown.
Pro members see all 26.
Pro members: see all 26 patents
Also on record, not counted in the 26: 26 patents in force now held by others · 2 patents ended · 42 applications pending · 11 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited